MREO - Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities
2024-04-10 04:08:49 ET
Summary
- Mereo BioPharma is a clinical-stage biopharmaceutical company focused on rare diseases and oncology treatments.
- Its flagship drugs include Setrusumab for Osteogenesis Imperfecta and Alvelestat for Alpha-1 Antitrypsin Deficiency.
- The company has signed out-licensed agreements for its drug candidates Navicixizumab and Leflutrozole, potentially earning $300 million and $65 million, respectively.
- Pre-revenue Mereo shows promise but targets limited markets for rare diseases, which conflicts with its high valuation multiple relative to peers.
Mereo BioPharma Group plc ( MREO ) is a clinical-stage biopharmaceutical company pioneer in rare diseases and oncology treatments. Setrusumab is one of its flagship drugs targeting Osteogenesis Imperfecta [OI], a genetic bone disorder. It has orphan drug designation in the EU and the US, and its development is currently done in partnership with Ultragenyx. It is in phase 3 of the clinical trials. Simultaneously, the drug Alvelestat finished phase 2 to treat Alpha-1 Antitrypsin Deficiency that produces Lung Disease [AATD-LD]. Lastly, Etigilimab is an innovative immunotherapy for treating solid tumors....
Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities